Tony W. Ho
2021
In 2021, Tony W. Ho earned a total compensation of $6.5M as Former EVP, Research and Development at CRISPR Therapeutics AG, a 68% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $210,150 |
|---|---|
| Option Awards | $2,787,434 |
| Salary | $467,000 |
| Stock Awards | $1,204,920 |
| Other | $1,854,139 |
| Total | $6,523,643 |
Ho received $2.8M in option awards, accounting for 43% of the total pay in 2021.
Ho also received $210.2K in non-equity incentive plan, $467K in salary, $1.2M in stock awards and $1.9M in other compensation.
Rankings
In 2021, Tony W. Ho's compensation ranked 1,916th out of 12,415 executives tracked by ExecPay. In other words, Ho earned more than 84.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,916 out of 12,415 | 85th |
Division Manufacturing | 723 out of 5,508 | 87th |
Major group Chemicals And Allied Products | 277 out of 2,378 | 88th |
Industry group Drugs | 236 out of 2,099 | 89th |
Industry Biological Products, Except Diagnostic Substances | 69 out of 449 | 85th |
Source: SEC filing on April 25, 2022.
Ho's colleagues
We found five more compensation records of executives who worked with Tony W. Ho at CRISPR Therapeutics AG in 2021.
2021
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
2021
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
2021
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
2021
James Kasinger
CRISPR Therapeutics AG
General Counsel
2021
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019